We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Pretomanid

News List

Trial reveals BPaL regimen for highly drug-resistant TB is effective even with reduced dose of linezolid expresspharma
July 16, 2021
This regimen reduces the treatment time for highly drug-resistant forms of TB from 18 months or longer to a six-month duration.
Mylan receives DCGI approval in India for TB drug, Pretomanid expresspharma
July 23, 2020
Pretomanid is only the third new anti-tuberculosis (TB) drug developed specifically for drug-resistant forms of the disease to be approved in more than 40 years.
FDA Approves Pretomanid for Highly Drug-Resistant Forms of Tuberculosis drugs
August 15, 2019
Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) for treating some of the most drug-resistant forms of tuberculosis (TB).
TB Alliance, Mylan Announce Collaboration to Commercialize Pretomanid americanpharmaceuticalreview
April 19, 2019
Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan announced a global collaboration to make the experimental drug pretomanid accessible for use in two investigational drug regimens for pulmonary tuberculosis (TB).